ClinicalTrials.gg
Not yet recruitingNCT07677384Updated Jun 30, 2026

A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder

A Phase 3 interventional study of HS-10506 in Insomnia Disorder, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The primary purpose of this open-label phase Ⅲ study is to evaluate the safety of HS-10506 on the incidence and severity of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI) in Chinese adult participants with insomnia disorder.

Read the detailed description

The study will comprise 4 periods : a Screening Period, a Run-in Period, an Open-Label Treatment Period during which participants will be treated for 4, 24, 36, or 48 consecutive weeks and a minimum 7-day Follow-up Period before an End of Study (EOS) Visit. The total study duration for each participant on this study is 2-13 months.

02

Conditions studied

  • Insomnia Disorder

Keywords

  • Clinical trial
  • insomnia disorder
  • open-label
  • long-term
  • phase 3
03

In context

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.

This study's planned enrollment of 600 is above the median of 68 across 2,355 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be 18 to 65 years of age (inclusive 18, not inclusive 65);
  2. Participants are required to voluntarily sign the form;
  3. (BMI): BMI (weight/height2 [kg/m2]) must be in the range of 18 to 35 kg/m2 (inclusive);
  4. For Participants completed Study 301: Participants have completed the Study 301, can potentially benefit from extended treatment with HS-10506 and have no major safety risks according to the investigator's clinical judgment;
  5. For new Participants: Participants must meet (5th edition) (DSM-5) criteria for insomnia disorder;
  6. For new Participants: Participants must have Insomnia Severity Index (ISI) scores≥15 at screening;
  7. For new Participants: Participants must have an sSOL≥30 minutes, sWASO≥30 minutes, and sTST\<6.5 hours for at least three nights every week within one month prior to screening; and sSOL≥30 minutes, sWASO≥30 minutes, and sTST\<6.5 hours for at least 3 nights from sleep diary in the last 7 consecutive days before the first dose in the open-label treatment period;

Exclusion criteria

Exclusion Criteria:

  1. Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;
  2. Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;
  3. Has used any medication that may affect the pharmacokinetics of HS-10506 or GLP-1R-related single/multi-target drugs within the past 2 weeks or 5 half-lives of the medication;
  4. Has used any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;
  5. Has a history of drug dependency or abuse within the past 1 year or showed positive in urine drug test at screening;
  6. Has a history of alcohol abuse within the past 1 year or can't obey the rules of alcohol restriction;
  7. Has a history of smoking≥10 cigars daily within the past 3 months or can't obey the rules of cigar restriction;
  8. Has a history of caffeine consumption≥600 mg per day or can't obey the rules of caffeine restriction;
  9. Has been working across 3 or more time zones or shift work within 2 weeks prior to screening;
  10. Has taken more than 3 naps per week for>1 hour each time within the past 2 weeks prior to screening;
  11. Has any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
  12. For Participants completed Study 301: Has been diagnosed with a sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder during Study 301, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
  13. For Participants completed Study 301: Has been diagnosed with neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases during Study 301; or other systemic diseases that are inappropriate for the study;
  14. For Participants completed Study 301: Previously participated in any clinical trial other than HS-10506-301 within 3 months prior to screening;
  15. For new Participants: Has history of/current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
  16. For new Participants: Has history of/current neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or clinically significant and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases within the past 3 months prior to screening; or other systemic diseases that are inappropriate for the study;
  17. For new Participants: Previously use of HS-10506;
  18. For new Participants: Previously participated in any clinical trial within 3 months prior to screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    HS-10506

    Participants will receive HS-10506 tablets, orally, once nightly for 4/24/36/48 consecutive weeks.

    Drug: HS-10506

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE)

    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

  2. Incidence and severity of serious adverse events (SAE)

    An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participants and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

  3. Incidence and severity of adverse events of special interest (AESI)

    An AESI (serious or non-serious) is any medical event specific to the investigational product or clinical trial.

    Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

Secondary outcomes

  1. Number of Participants With Clinically Significant Change in hematology

    Hematology tests will include hemoglobin, hematocrit, red blood cell count, platelets, white blood cell count, count and absolute lymphocytes, neutrophils, basophils, eosinophils, monocytes. Any clinically significant change in hematological values will be determined at the investigator's discretion

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 48

  2. Number of Participants With Clinically Significant Change in clinical chemistry

    Clinical chemistry tests will include total and direct bilirubin, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, albumin, total protein, creatinine, glucose, hemoglobin A1c (HbA1c), creatinine kinase. Any clinically significant change in clinical chemistry values will be determined at the investigator's discretion.

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 48

  3. Number of Participants With Clinically Significant Change in urinalysis

    Urinalysis will include glucose, ketones, urine red blood cells, urine white blood cells. Any clinically significant change in urinalysis values will be determined at the investigator's discretion.

    Time frame: Baseline, Week 12, Week 24, Week 36, Week 48

  4. Withdrawal symptoms by Physician Withdrawal Checklist (PWC-20)

    The PWC-20 is a 20-item questionnaire and the score of each item ranges from 0-3 (0=not present, 1=mild, 2=moderate, 3=severe) with higher scores indicating greater severity of withdrawal symptoms

    Time frame: The day after the last administration and at least 7 days after discontinuation of the medication

  5. Rebound insomnia by subjective sleep onset latency (sSOL) during the follow-up period

    Time frame: Baseline, Follow-up Period (7-9 days)

  6. Rebound insomnia by subjective wake after sleep onset (sWASO) during the follow-up period

    Time frame: Baseline, Follow-up Period (7-9 days)

  7. Rebound insomnia by subjective total sleep time (sTST) during the follow-up period

    Time frame: Baseline, Follow-up Period (7-9 days)

  8. Change from baseline in subjective sleep onset latency (sSOL) under the treatment of HS-10506

    sSOL: estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary

    Time frame: Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months)

  9. Change from baseline in subjective sleep efficiency (sSE) under the treatment of HS-10506

    sSE: the ratio of subjective total sleep time (sTST) to subjective time in bed

    Time frame: Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months)

  10. Change from baseline in subjective wake after sleep onset (sWASO) under the treatment of HS-10506

    sWASO: estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary

    Time frame: Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months)

  11. Change from baseline in subjective total sleep time (sTST) under the treatment of HS-10506

    sTST: the total sleep time reported by the participant in sleep diary

    Time frame: Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2029, 36 months later.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 36 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 30, 2026
StartEst.
Jun 12, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07677384
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jun 12, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jun 30, 2026

Study contacts

Yuping Wang, Principal Investigator
Contact
wangyuping01@sina.cn
13501186298

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10506

Start the discussion